Selpercatinib is the first drug from Loxo’s pipeline that Lilly has brought to market. Prior to the acquisition, Loxo won approval of Vitrakvi, which targets a different genetic mutation and is sold by Bayer AG. Matthew Price, community development manager at Brain Tumour Research said: ‘We’re really grateful to Weronika for taking part in the […]